Narrative review / 2016
Endoscopic bariatric therapies provide minimally invasive treatment options for obesity and related metabolic comorbidities.
This review evaluates current and emerging endoscopic bariatric therapies for obesity and associated cardio-metabolic comorbidities. Currently, two intragastric balloons have FDA approval for 6-month implantation in patients with a BMI of 30-40 kg/m². Additionally, full-thickness suturing has enabled primary endoscopic sleeve gastroplasty and Roux-en-Y gastric bypass revision as viable alternatives to surgery.
- Study type
- Narrative review
- Who was studied
- Patients with obesity (e.g., BMI range of 30-40 kg/m²)
- What was measured
- Efficacy, procedural technique, and evidence for endoscopic bariatric therapies
THE PAPER
Endoscopic Bariatric Therapies.
Goyal D, Watson RR. Curr Gastroenterol Rep, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.